ProCE Banner Activity

ADVANCE: DTG + FTC/(TAF or TDF) Noninferior to EFV/FTC/TDF in ART-Naive Patients in South Africa

Slideset Download
Conference Coverage
Phase III trial supports use of DTG-based regimens, with low rates of emergent resistance and no INSTI resistance.

Released: July 29, 2019

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

Educational grant provided by:

Gilead

ViiV Healthcare

Partners

IAS 2018

ProCE Banner

IAS 2019

ProCE Banner